Virpax^® Pharmaceuticals Inc., (Nasdaq: VRPX) is a specialty pharmaceutical company focused on pioneering advanced healthcare solutions with Probudur, its flagship product leveraging proprietary liposomal encapsulation. Designed for sustained release, Probudur may extend local anesthetic at the wound/incision site, effectively managing post-operative pain for 96 hours as evidenced by non-clinical study data.

Collaborating through Cooperative Research and Development Agreements (CRADA) and partnering with prestigious institutions like the National Institute of Health/NCATS and U.S. Army Institute of Surgical Research/Department of Defense, we are committed to developing non-addictive treatments. Additionally, our involvement in the Epilepsy Therapy Screening Program (ETSP) underscores our dedication to addressing drug-resistant epilepsy and rare diseases.

With a focus on optimizing non-addictive medications, our drug delivery platforms target unmet global needs in markets such as Post Operative Pain, Severe Pain, Post Cancer Pain, and Rare Pediatric Epilepsy, including orphan diseases like Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome. Virpax is at the forefront of providing differentiated solutions for these diverse healthcare challenges.